Loading…
A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single su...
Saved in:
Published in: | Balkan journal of medical genetics 2014-12, Vol.17 (2), p.73-80 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3 |
---|---|
cites | |
container_end_page | 80 |
container_issue | 2 |
container_start_page | 73 |
container_title | Balkan journal of medical genetics |
container_volume | 17 |
creator | Soysal, D. Kızıldağ, S. Saatlı, B. Posacı, C. Soysal, S. Koyuncuoğlu, M. Doğan, Ö. E. |
description | Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis. |
doi_str_mv | 10.2478/bjmg-2014-0077 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b49f210a36284fc8afb4c606c363edf1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b49f210a36284fc8afb4c606c363edf1</doaj_id><sourcerecordid>1678748188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3</originalsourceid><addsrcrecordid>eNp1kUFv1DAQRiMEoqVw5Yhy5JLisZ3YKySkpSqwUgEJwYmD5djjrFdJvNjOovLrSbqlag8cLI9mPr-x9IriJZBzyoV80-6GrqIEeEWIEI-KU2AAFYGGPL5XnxTPUtoR0jAB4mlxQusVE5LAafFzXX4JB-zL9dj50OGIyadyM25963OI5Xs8aOP_TINu566dDKZyvQ_7HJacH8u8xfKbzuXlaMOAOfqbwedgsX9ePHG6T_ji9j4rfny4_H7xqbr6-nFzsb6qTE1kroyEBg21UBtNKK9XshYooUYuHFsJSjh3GogArRnOhztBzMoyRKTOEsvOis2Ra4PeqX30g47XKmivbhohdkrH7E2PquUrR4Fo1lDJnZHatdw0pDGsYWgdzKx3R9Z-age0Bsccdf8A-nAy-q3qwkFxDozzega8vgXE8GvClNXgk8G-1yOGKSlohBRcgpRz9PwYNTGkFNHdrQGiFrtqsasWu2qxOz94df9zd_F_OufA22Pgt-4zRotdnK7nQu3CFMfZwX_IIKhg7C8SKbWn</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1678748188</pqid></control><display><type>article</type><title>A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model</title><source>PubMed Central Free</source><source>Publicly Available Content (ProQuest)</source><creator>Soysal, D. ; Kızıldağ, S. ; Saatlı, B. ; Posacı, C. ; Soysal, S. ; Koyuncuoğlu, M. ; Doğan, Ö. E.</creator><creatorcontrib>Soysal, D. ; Kızıldağ, S. ; Saatlı, B. ; Posacı, C. ; Soysal, S. ; Koyuncuoğlu, M. ; Doğan, Ö. E.</creatorcontrib><description>Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.</description><identifier>ISSN: 1311-0160</identifier><identifier>EISSN: 1311-0160</identifier><identifier>DOI: 10.2478/bjmg-2014-0077</identifier><identifier>PMID: 25937801</identifier><language>eng</language><publisher>Poland: De Gruyter Open</publisher><subject>Angiogenesis ; Apoptosis ; Bevacizumab ; Endometriosis ; Original</subject><ispartof>Balkan journal of medical genetics, 2014-12, Vol.17 (2), p.73-80</ispartof><rights>Macedonian Academy of Sciences and Arts 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413445/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413445/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25937801$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soysal, D.</creatorcontrib><creatorcontrib>Kızıldağ, S.</creatorcontrib><creatorcontrib>Saatlı, B.</creatorcontrib><creatorcontrib>Posacı, C.</creatorcontrib><creatorcontrib>Soysal, S.</creatorcontrib><creatorcontrib>Koyuncuoğlu, M.</creatorcontrib><creatorcontrib>Doğan, Ö. E.</creatorcontrib><title>A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model</title><title>Balkan journal of medical genetics</title><addtitle>Balkan J Med Genet</addtitle><description>Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.</description><subject>Angiogenesis</subject><subject>Apoptosis</subject><subject>Bevacizumab</subject><subject>Endometriosis</subject><subject>Original</subject><issn>1311-0160</issn><issn>1311-0160</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kUFv1DAQRiMEoqVw5Yhy5JLisZ3YKySkpSqwUgEJwYmD5djjrFdJvNjOovLrSbqlag8cLI9mPr-x9IriJZBzyoV80-6GrqIEeEWIEI-KU2AAFYGGPL5XnxTPUtoR0jAB4mlxQusVE5LAafFzXX4JB-zL9dj50OGIyadyM25963OI5Xs8aOP_TINu566dDKZyvQ_7HJacH8u8xfKbzuXlaMOAOfqbwedgsX9ePHG6T_ji9j4rfny4_H7xqbr6-nFzsb6qTE1kroyEBg21UBtNKK9XshYooUYuHFsJSjh3GogArRnOhztBzMoyRKTOEsvOis2Ra4PeqX30g47XKmivbhohdkrH7E2PquUrR4Fo1lDJnZHatdw0pDGsYWgdzKx3R9Z-age0Bsccdf8A-nAy-q3qwkFxDozzega8vgXE8GvClNXgk8G-1yOGKSlohBRcgpRz9PwYNTGkFNHdrQGiFrtqsasWu2qxOz94df9zd_F_OufA22Pgt-4zRotdnK7nQu3CFMfZwX_IIKhg7C8SKbWn</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Soysal, D.</creator><creator>Kızıldağ, S.</creator><creator>Saatlı, B.</creator><creator>Posacı, C.</creator><creator>Soysal, S.</creator><creator>Koyuncuoğlu, M.</creator><creator>Doğan, Ö. E.</creator><general>De Gruyter Open</general><general>Macedonian Science of Sciences and Arts</general><general>Sciendo</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20141201</creationdate><title>A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model</title><author>Soysal, D. ; Kızıldağ, S. ; Saatlı, B. ; Posacı, C. ; Soysal, S. ; Koyuncuoğlu, M. ; Doğan, Ö. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Angiogenesis</topic><topic>Apoptosis</topic><topic>Bevacizumab</topic><topic>Endometriosis</topic><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soysal, D.</creatorcontrib><creatorcontrib>Kızıldağ, S.</creatorcontrib><creatorcontrib>Saatlı, B.</creatorcontrib><creatorcontrib>Posacı, C.</creatorcontrib><creatorcontrib>Soysal, S.</creatorcontrib><creatorcontrib>Koyuncuoğlu, M.</creatorcontrib><creatorcontrib>Doğan, Ö. E.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><jtitle>Balkan journal of medical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soysal, D.</au><au>Kızıldağ, S.</au><au>Saatlı, B.</au><au>Posacı, C.</au><au>Soysal, S.</au><au>Koyuncuoğlu, M.</au><au>Doğan, Ö. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model</atitle><jtitle>Balkan journal of medical genetics</jtitle><addtitle>Balkan J Med Genet</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>17</volume><issue>2</issue><spage>73</spage><epage>80</epage><pages>73-80</pages><issn>1311-0160</issn><eissn>1311-0160</eissn><abstract>Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.</abstract><cop>Poland</cop><pub>De Gruyter Open</pub><pmid>25937801</pmid><doi>10.2478/bjmg-2014-0077</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1311-0160 |
ispartof | Balkan journal of medical genetics, 2014-12, Vol.17 (2), p.73-80 |
issn | 1311-0160 1311-0160 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_b49f210a36284fc8afb4c606c363edf1 |
source | PubMed Central Free; Publicly Available Content (ProQuest) |
subjects | Angiogenesis Apoptosis Bevacizumab Endometriosis Original |
title | A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A24%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Novel%20Angiogenesis%20Inhibitor%20Bevacizumab%20Induces%20Apoptosis%20in%20the%20Rat%20Endometriosis%20Model&rft.jtitle=Balkan%20journal%20of%20medical%20genetics&rft.au=Soysal,%20D.&rft.date=2014-12-01&rft.volume=17&rft.issue=2&rft.spage=73&rft.epage=80&rft.pages=73-80&rft.issn=1311-0160&rft.eissn=1311-0160&rft_id=info:doi/10.2478/bjmg-2014-0077&rft_dat=%3Cproquest_doaj_%3E1678748188%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1678748188&rft_id=info:pmid/25937801&rfr_iscdi=true |